5. ACUTE KIDNEY INJURY
Definition
Sudden deterioration in renal function
It results in the inability of the kidneys to maintain fluid and electrolyte homeostasis.
Also results in a decline in GFR, retention of urea and other nitrogenous waste products
8/12/2022 5
7. Prevalence
Occurs in 2-3% of children admitted to pediatric tertiary care centers and in as many as 8% of
infants in NICU.
8/12/2022 7
8. Pathophysiology of AKI
Three major factors that may account for the development of AKI:
Renal hemodynamics
nephronal factors
metabolic/cellular factors
8/12/2022 8
9. cont…
Renal hemodynamics
Insult to the renal tubular epithelium results in release of vasoactive compounds
increase cortical vascular resistance causing decreased RBF
Release of vasoconstrictive compounds may then diminish GFR by constricting afferent and
efferent arterioles
thereby causing diminished urine output, or oliguria
8/12/2022 9
10. Cont…
Nephronal factors:
proximal tubule injury leading to epithelial necrosis and loss of tubular integrity and
impacted cellular debris
Back leak of solute/fluid and tubule obstruction which further lead to diminished GFR and
tubule flow
8/12/2022 10
11. cont…
Cellular and metabolic mechanisms
Oxygen free radical production contributing to an ischemic insult
Calcium accumulation in tissues which has undergone necrosis contributing to renal cell injury:
uncouples oxidative phosphorylation
activation of membrane bound phospholipases
activation of intracellular proteases
inhibition of Na/K-ATPase
Direct effect on intracellular pH.
8/12/2022 11
12. Cont…
Depletion of tissue adenine nucleotide levels which is a source of energy and concomitant
increase in nucleosides, adenosine and inosine.
These are responsible for renal vasoconstriction following an ischemic insult.
8/12/2022 12
13. Etiology of ARF
The causes and mechanisms of AKI can be classified based on the anatomic location of the initial
injury:-
Vascular – Blood from the renal arteries is delivered to the glomeruli. Interruption of perfusion to
the kidneys results in prerenal AKI
Glomeruli – Ultrafiltration occurs at the glomeruli forming an ultrafiltrate, which subsequently
flows into the renal tubules
Renal tubule – Reabsorption and secretion of solute and/or water from the ultrafiltrate occurs
within the tubules
Urinary tract – cause postrenal AKI
8/12/2022 13
14. Cont…
1. Prerenal ARF also called prerenal azotemia
• Due to diminished effective circulating arterial volume → inadequate renal perfusion and a
decreased GFR.
• Evidence of kidney damage is absent
• If the underlying cause of the renal hypoperfusion is reversed promptly renal function
returns to normal.
• If hypoperfusion is sustained, intrinsic renal parenchymal damage can develop
8/12/2022 14
15. Cont…
2. Intrinsic renal ARF
• renal parenchymal damage, including sustained hypoperfusion and ischemia.
• Many forms of glomerulonephritis can cause ARF
• Ischemic/hypoxic injury and nephrotoxic insults are the most common causes of intrinsic AKI
in the United States
• recovery in 1-2 weeks
8/12/2022 15
16. Cont…
Three phases of intrinsic renal failure
Initiation phase- GFR ↓because of decreased glomerular pressure, obstructed flow by casts, necrotic
debris and back leak of filtrate through injured epithelium.
Maintenance phase(1-2wks)
renal cell injury is established
GFR remains relatively low for several days
UOP will be lowest
uremic complications start to appear
Recovery phase:
Renal parenchymal cell repair & regeneration
GFR starts to increase
retained salt and water will be excreted
8/12/2022 16
17. cont...
Postrenal ARF
It includes a variety of disorders characterized by obstruction of the urinary tract
Obstruction must be bilateral to result in AKI
Relief of the obstruction usually results in recovery of renal function except in patients with
associated renal dysplasia or prolonged urinary tract obstruction.
8/12/2022 17
19. Clinical manifestation and diagnosis
A carefully taken history is critical in defining the cause of ARF
Thorough physical examination is a must
Careful attention to volume status!
• Tachycardia, dry mucous membranes, and poor peripheral perfusion
• Peripheral edema, rales, and a cardiac gallop
• rash and arthritis might indicate systemic lupus erythematosus(SLE)
• Palpable flank masses – Renal vein thrombosis, Tumor, Urinary tract obstruction
8/12/2022 19
22. Cont…
The sensitivity and specificity of urine sodium of <20 in differentiating prerenal azotemia
from ATN are 90% and 82%, respectively.
Fractional excretion of sodium is :
• urine to plasma (U/P) of sodium divided by U/P of creatinine × 100.
• The sensitivity and specificity of FENa of <1% in differentiating prerenal azotemia from
ATN are 96% and 95%, respectively
Biomarkers of AKI - serum Cr is often a delayed and imprecise test
NGAL, KIM-1, and IL-18 show promise in both their diagnostic and prognostic utility
may allow for early intervention prior to the onset of SCr rise, severe metabolic
derangements and fluid overload
8/12/2022 22
23. Acute Renal Failure in neonate
sudden impairment in renal function
Lead to an inability of the kidneys to excrete nitrogenous waste
Although the criteria for neonatal ARF have varied among studies, a consensus definition is a
serum creatinine level of more than 1.5 mg/dL
8/12/2022 23
25. Cont…
Prevalence
Most reports estimate the incidence of ARF in the hospitalized neonatal population to be 6%
to 8%
although some estimates reach as high as 23%
8/12/2022 25
27. Clinical presentation
Failure to void for longer than 48 hours may suggest impairment of renal function and should
prompt further investigation
Oliguria, systemic hypertension, cardiac arrhythmia
evidence of fluid overload or dehydration
decreased activity, seizure, vomiting and anorexia
8/12/2022 27
28. Evaluation
History
A neonate with a history of hydronephrosis seen on prenatal ultrasound studies and a
palpable bladder most likely has congenital urinary tract obstruction, probably related to
posterior urethral valves.
perinatal asphyxia, the pre- or postnatal administration of potentially nephrotoxic drugs
Family history of renal disease.
P/E should focus on
signs of volume depletion or volume overload
abdomen, genitalia and search for other congenital anomalies
8/12/2022 28
29. Laboratory finding
In general, each doubling of the serum creatinine level represents an approximately 50%
reduction in GFR
elevated serum creatinine and BUN, hyperkalemia, metabolic acidosis, hypocalcemia,
hyperphosphatemia
Accurate estimate of GFR can be calculated as:-
8/12/2022 29
30. Diagnostic Indexes in Acute Renal Failure
TEST PRERENAL ARF INTRINSIC ARF
BUN/Cr ratio (mg/mg) >30 <20
FENa (%) ≤2.5 ≥3.0
Urinary Na (mEq/L) ≤20 ≥50
Urinary Osm (mOsm/kg) ≥350 ≤300
Urinary specific gravity >1.012 <1.014
Ultrasonography Normal May be abnormal
Response to volume challenge UO > 2 mL/kg/h No increase in UO
8/12/2022 30
31. Management of ARF
Specific treatment of the underlying cause
Fluid management
Electrolyte management
Nutritional support
Adjustment of drug dosing
Renal replacement therapy
Specific pharmacologic therapies
8/12/2022 31
32. Fluid Management
Hypovolemia:- IV fluid therapy given as a NS bolus (10 to 20 mL/kg over 30 minutes, repeated
twice as needed)
attempt to restore renal function
prevent the progression of prerenal AKI to intrinsic AKI
hypovolemic patients generally void within 2 hr
Failure to do so suggests intrinsic or postrenal AKI
8/12/2022 32
33. Cont…
Euvoluemia:- Ongoing fluid losses should be balanced
Insensible fluid [300 to 500 mL/m 2 per day]
higher in febrile patients and lower for ventilated patients
urine , blood loss and gastrointestinal losses should be replaced
8/12/2022 33
34. Cont…
Hypervolemia
Child with signs of fluid overload (edema, heart failure and pulmonary edema) requires fluid
removal and/or fluid restriction
omitting the replacement of insensible fluid losses, urine output, and extrarenal losses to
diminish the expanded intravascular volume
8/12/2022 34
35. Cont…
Diuretic therapy :- Only after the adequacy of the circulating blood volume has been established
Furosemide (2-4 mg/kg)
Bumetanide (0.1 mg/kg) may be given as an alternative to furosemide
mannitol (0.5 g/kg) may be administered as a single IV dose
If urine output is not improved, then a continuous diuretic infusion (0.1 to 0.3 mg/kg per
hour) may be started
To increase renal cortical blood flow, many clinicians administer dopamine (2-3 μg/kg/min) in
conjunction with diuretic therapy
There is little evidence that diuretics or dopamine can prevent AKI hasten recovery
8/12/2022 35
36. Electrolyte management
Hyperkalemia:- (K+ > 6 mEq/L)
Lead to cardiac arrhythmia, cardiac arrest, and death
Exogenous potassium restriction
Resin therapy :- 1 g/kg orally or by retention enema
- A single dose expected to lower the serum K+ level by about 1 mEq/L
- can be repeated after 2hrs
When it is >7mEq/L, it requires emergency measures
• Calcium gluconate 10% solution, 1.0 mL/kg IV, over 3–5 min
• Sodium bicarbonate, 1–2 mEq/kg IV, over 5–10 min
• Regular insulin, 0.1 U/kg, with glucose 50% solution, 1 mL/kg, over 1 hr
8/12/2022 36
37. Cont…
Metabolic Acidosis
because of the retention of hydrogen ions, phosphate, and sulfate
but it rarely requires treatment
treat if acidosis is severe (arterial pH < 7.15; serum bicarbonate < 8 mEq/L) or
If contributes to significant hyperkalemia
the intravenous route, generally by giving enough bicarbonate to raise the arterial pH to 7.20
8/12/2022 37
38. Cont…
Hyponatremia:
- most commonly a dilutional disturbance that must be corrected by fluid restriction rather
than sodium chloride administration.
- Hypertonic (3%) saline for symptomatic hyponatremia (seizures, lethargy) or those with a
serum sodium level <120 mEq/L
- Acute correction of the serum sodium to 125 mEq/L(mmol/L) should be accomplished
8/12/2022 38
39. Cont…
Hypocalcemia
primarily treated by lowering the serum phosphorus level
Calcium should not be given intravenously, except in cases of tetany, to avoid deposition of
calcium salts into tissues
Seizures
Due to hypertensive encephalopathy, hyponatremia, hypocalcemia, cerebral hemorrhage,
cerebral vasculitis, and uremic state
Benzodiazepines are the most effective agents in acutely controlling seizures
subsequent therapy should be directed toward the precipitating cause
8/12/2022 39
40. Cont…
Hypertension:-
Due to hyperreninemia and expansion of the ECF volume
most common in AKI patients with AGN or HUS
Salt and water restriction is critical
Children with severe symptomatic hypertension (hypertensive urgency or emergency)
- continuous infusions of nicardipine (0.5-5.0 μg/kg/min)
- sodium nitroprusside (0.5-10.0 μg/kg/min)
- labetalol (0.25-3.0 mg/kg/hr), or esmolol (150-300 μg/kg/min
8/12/2022 40
41. Cont…
Anemia:- usually mild (Hgb 9-10g/dl) and due to hemodilution
Transfuse with packed RBC in children with HUS, SLE, active bleeding or Prolonged AKI and
Hgb <7g/dl
Slow (4-6 hr) transfusion with packed RBC(10 mL/kg) diminishes the risk of hypervolemia
In the presence of severe hypervolemia or hyperkalemia, blood transfusions are most safely
administered during dialysis or ultrafiltration.
8/12/2022 41
42. Dialysis
Indications
Anuria/oliguria
Volume overload with evidence of hypertension and/or pulmonary edema refractory
to diuretic therapy
Persistent hyperkalemia
Severe metabolic acidosis unresponsive to medical management
Uremia (encephalopathy, pericarditis, neuropathy)
BUN >100-150 mg/dL (or lower if rapidly rising)
8/12/2022 42
43. Prognosis
depends entirely on the nature of the underlying disease process rather than on the renal failure
itself
AKI caused by a renal-limited condition such as postinfectious AGN have a very low mortality rate
(<1%)
Those with AKI related to multiorgan failure have a very high mortality rate (>50%)
Recovery of renal function is likely after AKI resulting from prerenal causes, ATN, acute interstitial
nephritis, or TLS
Complete recovery of renal function is unusual when AKI results from most types of rapidly
progressive glomerulonephritis, bilateral renal vein thrombosis, or bilateral cortical necrosis
8/12/2022 43
44. Cont…
In neonates
Mortality rates range from 14% to 73%.
In general, those infants with prerenal ARF who receive prompt treatment for renal
hypoperfusion have an excellent prognosis
Infants with postrenal ARF related to congenital urinary tract obstruction have a variable
outcome, which depends on the degree of associated renal dysplasia
long-term sequelae seen in survivors of neonatal ARF include HTN, an impaired capacity for
urinary concentration, renal tubular acidosis (RTA), and impaired renal growth
8/12/2022 44
45. Reference
Beth A. Vogt Katherine MacRae Dell Ira D. Davis, Fanaroff
Devarajan P. Acute kidney injury: Nat Rev Nephrol . 2017, 21st edition Nelson
KDIGO Guidelines on AKI Professor Alan Cass, Director Menzies School of Health Research
President-Elect ANZ Society of Nephrology
Rajasree Sreedharan . Prasad Devarajan . Scott K. Van Why, 6th edition of pediatric Nephrology
Robert H Squires, Jr, MD, FAAP, Oct 2013
8/12/2022 45
Anatomy of kidney
It is a retroperitoneal organ
Lies above the level of the umbilicus.
It has an outer layer the cortex, which contains the glomeruli, proximal and distal tubules, and collecting ducts
An inner layer the medulla, which contains the straight portions of the tubules, the loops of Henle, the vasa recta and the terminal collecting ducts.
Blood supply:
Consists of a main renal artery that arises from the aorta
Receive 20% of cardiac out put
Each kidney consists of approximately 1 million nephrons (glomeruli and associated tubules).
The glomerular network of specialized capillaries serves as the filtering mechanism of the kidney.
Furosemide — A trial of furosemide may be attempted to induce a diuresis and convert AKI from an oliguric to a non-oliguric form, thereby simplifying fluid and nutritional management. However, loop diuretic therapy does not significantly alter the natural course of AKI. The dissociation between increasing the urine output and not affecting the course of AKI with diuretic therapy probably reflects the ability of the diuretic to enhance the urine output in those few nephrons that are still functioning. However, there is no effect on nonfunctioning nephrons, and as a result, there is no effect on the course of the renal failure. (See "Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis", section on 'Diuretics' .)
If a trial of furosemide is used, it should be given as a single high-dose bolus (2 to 5 mg/kg/dose) to children in the early stages of oliguric AKI with hypervolemia (ie, oliguria of less than 24 hours’ duration). If the diuretic bolus is effective, a continuous infusion of furosemide (0.1 to 0.3 mg/kg per hour) may be started. Furosemide should be promptly discontinued if the bolus doses do not result in a diuretic response within two hours of bolus administration. The risk of ototoxicity and renal toxicity from furosemide use in this setting is significant due to potential elevated serum levels. Care should also be taken to avoid hypotension from overuse of diuretic therapy as this might result in further kidney injury and in some cases, increase mortality. Loop diuretics should not be used as prolonged therapy for established AKI, but given for a short length of time for volume control in responsive patients because of the risk of adverse effects.
PREVENTION OF ACUTE KIDNEY INJURY (AKI)
Proven measures — General measures to prevent AKI include:
Fluid administration in some settings, such as hypovolemia
Avoidance of hypotension by providing inotropic support in critically-ill children following adequate volume repletion (see "Initial management of shock in children", section on 'Early goal-directed therapy' )
Readjustment of nephrotoxic medications based on close monitoring of renal function and drug levels
Fluid administration — Fluid administration in the following settings has successfully prevented AKI:
Pre-renal AKI due to hypovolemia – In children with a history and physical findings consistent with hypovolemia, administration of an intravenous fluid bolus with normal saline (10 to 20 mL/kg over 30 minutes) may prevent more severe intrinsic AKI. The bolus can be repeated twice if necessary, until urine output is re-established. Fluid challenge is contraindicated in patients with obvious volume overload or heart failure.
At-risk patients for AKI – Volume expansion has been successful in preventing AKI in patients at-risk for AKI with the following conditions (see "Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis", section on 'Optimizing volume status' ).
Hemoglobinuria and myoglobinuria (see "Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)" )
Administration of potential nephrotoxins, such as aminoglycosides, amphotericin B , radiocontrast media, cisplatin , and intravenous acyclovir (see "Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity", section on 'Prevention' and "Amphotericin B nephrotoxicity", section on 'Prevention' and "Prevention of contrast-induced nephropathy", section on 'Prevention' and "Cisplatin nephrotoxicity", section on 'Prevention' and "Acyclovir: An overview", section on 'Acute renal failure' )
Tumor lysis syndrome (see "Tumor lysis syndrome: Prevention and treatment", section on 'Prevention' )
Surgical procedures, in which there is a reduction in the intravascular volume during either the intraoperative or postoperative period (see "Intraoperative fluid management", section on 'Hypovolemia and reduced tissue perfusion' and "Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis", section on 'Surgery' )
Nephrotoxin management — The impact of nephrotoxic drugs on the development of AKI in children was illustrated in a retrospective single center study of 1660 noncritical-ill hospitalized children [ 9 ]. Children who developed AKI as defined by the serum creatinine-based pRIFLE criteria ( table 1 ) were more likely to be exposed to one or more nephrotoxic medications than patients without AKI (odd ratio [OR] 1.7; 95% CI 1.04-2.9). The RIFLE criteria consists of three graded levels of injury (Risk, Injury, and Failure) based upon either the magnitude of elevation in serum creatinine or urine output, and two outcome measures (Loss and End-stage renal disease). Both increasing dose and duration of nephrotoxin use were associated with increased development of AKI.
As a result, monitoring serum creatinine (ie, measure of kidney function) and drug level (if possible) is important as it enables appropriate adjustment of drug dosing based on the knowledge of altered pharmacokinetics in early AKI [ 10 ]. In addition, clinicians should also monitor drug efficacy and toxicity. However, readjustment of drugs is often challenging as renal function changes and if drug monitoring is not available, as discussed below. (See 'Drug management' below.)
Unproven pharmacologic agents — Several pharmacologic agents including mannitol , loop diuretics, low-dose dopamine, fenoldopam , atrial natriuretic peptide, and N- acetylcysteine have been studied in the prevention of AKI. However, none of these agents have been shown to be of proven benefit. (See "Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis" .)
Mannitol — Experimental animal studies suggested that mannitol might be protective by causing a diuresis (thereby minimizing intratubular cast formation) and by acting as a free radical scavenger (thereby minimizing cell injury). In the clinical setting, the efficacy of mannitol for prevention of AKI is inconclusive, and its use can result in significant side effects including volume expansion, hyperosmolality, pulmonary edema and AKI. Its use for prevention of AKI is not recommended. (See "Complications of mannitol therapy", section on 'Complications' .)
Loop diuretics — Loop diuretics such as furosemide induce a diuresis by reducing active NaCl transport in the thick ascending limb of the loop of Henle. It has been proposed that the ensuing decrease in energy requirement may be protective of renal tubule cells, which may be faced with a decrease in energy delivery due to renal hypoperfusion or injury. However, the available evidence from adult clinical studies does not support the routine use of diuretics as a preventive measure for AKI, and in some settings, diuretic use was associated with an increase in serum creatinine. As a result, the routine use of loop diuretics to prevent AKI is not recommended. (See "Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis", section on 'Diuretics' .)
Dopamine — The use of low “renal-dose” of the inotropic agent dopamine (0.5 to 3 mg/kg/min) is common in the critical care setting due to its renal vasodilatory and natriuretic effects [ 5 ]. However, prospective randomized studies of adult patients at risk for AKI have not shown a beneficial renoprotective effect of “low-dose” dopamine. In addition, there are significant side effects of dopamine therapy including tachycardia, arrhythmias, myocardial ischemia, and intestinal ischemia. Therefore, the routine use of dopamine for prevention of AKI is not recommended. (See "Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis", section on 'Dopamine' .)
Fenoldopam — Fenoldopam is a potent, short-acting, selective dopamine A-1 receptor agonist that increases renal blood flow and decreases systemic vascular resistance [ 11 ]. Data are limited in the use of this agent in children at-risk for AKI.
In a small retrospective study of 13 critically-ill children receiving fenoldopam , a significant increase in urine output and a reduction in BUN within 24 hours were noted [ 12 ].
In a small, prospective, single-center randomized, double-blind, controlled trial of 80 children undergoing cardiac surgery requiring cardiopulmonary bypass, patients who received fenoldopam compared with those treated with placebo had lower urinary neutrophil gelatinase-associated lipocalin and cystatin C levels (AKI biomarkers) at the end of surgery, and 12 hours after admission into the pediatric intensive care unit [ 13 ]. There was also a reduction in the use of diuretics ( furosemide ) and vasodilators ( phentolamine ) in the fenoldopam group (OR 0.22; 95% CI 0.07-0.7).
Similar results have been reported in adults. However, because of the heterogeneity amongst studies and inability to verify changes in glomerular filtration rate, the benefits of fenoldopam must be confirmed in large randomized, controlled trials prior to routine recommendation of this agent for the prevention of AKI. (See "Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis", section on 'Fenoldopam' .)
Natriuretic peptides — Atrial natriuretic peptide (ANP) and b-type natriuretic peptide (BNP) block tubular reabsorption of sodium and vasodilate the afferent arteriole. The renoprotective effects of these agents have been evaluated primarily in trials of adults undergoing cardiac surgery. (See "Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis", section on 'Atrial natriuretic peptide' .)
Pediatric data for the renoprotective effects of natriuretic peptides are limited. In a small retrospective study of 20 children with decompensated heart failure, recombinant human b-type natriuretic peptide ( nesiritide ) resulted in increased urine output and decreased serum creatinine concentrations [ 14 ]. Because of the paucity of data, the routine use of natriuretic peptides for prophylaxis against AKI is not recommended.
N-acetylcysteine — N- acetylcysteine (NAC) is a free radical scavenger antioxidant agent that counteracts the deleterious effects of reactive oxygen species in the generation of tubular injury and also has vasodilatory properties. In adults, several meta-analyses have demonstrated NAC did not provide any additional benefit to placebo in the prevention of AKI in adults following surgery. Although data regarding the use of oral NAC in prevention of contrast-nephropathy in adults are equivocal, NAC is often administered to high-risk patients undergoing a radiologic study that requires the administration of radiocontrast media as it is a well tolerated drug with minimal side effects. (See "Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis", section on 'N-acetylcysteine' and "Prevention of contrast-induced nephropathy", section on 'Acetylcysteine' .)
While NAC is commonly used in children for treatment of acetaminophen toxicity and other forms of acute liver failure, there are no data for its renoprotective effects in the pediatric population. The routine use of NAC for AKI prophylaxis in children is therefore not recommended, with the possible exception of judicious use in children at high-risk for contrast-induced nephropathy.
Critically-ill children — In critically-ill children, the degree of fluid overload is an independent risk factor for mortality, irrespective of severity of illness [ 15,16 ]. This was illustrated in a study of 297 children who received continuous renal replacement therapy from the Prospective Pediatric Continuous Renal Replacement Therapy (ppCRRT) Registry Group [ 15 ]. Mortality rates for patients who developed fluid overload greater than 20 percent, between 10 and 20 percent, and less than 10 percent were 66, 43, and 29 percent, respectively. After adjusting for severity of illness and intergroup differences, there was a 3 percent increase in mortality for each 1 percent increase in severity of fluid overload.
As discussed above, in children with AKI, the fluid status should be determined. We utilize the equation from the 2007 updated American College of Critical Care Medicine Clinical Guidelines for Hemodynamic Support of Neonates and Children with Septic Shock as follows [ 17 ]:
Percent fluid overload = [total fluid in (Liters) – fluid out (Liters)]/admission weight (kg) x 100
Renal replacement therapy (RRT) should be strongly considered for critically-ill children with AKI who are not expected to recover kidney function expeditiously when fluid overload exceeds 10 percent and is performed for those with fluid overload greater than 15 percent. (See "Pediatric acute kidney injury: Indications, timing, and choice of modality for renal replacement therapy (RRT)", section on 'Fluid overload' .)